High initial levels of comorbidity in patients with RA selected to receive biologic agents
- Select a language for the TTS:
- UK English Female
- UK English Male
- US English Female
- US English Male
- Australian Female
- Australian Male
- Language selected: (auto detect) - EN
Play all audios:
Hyrich K et al. (2006) Baseline comorbidity levels in biologic and standard DMARD treated patients with rheumatoid arthritis: results from a national patient register. Ann Rheum Dis 65:
895–898
Although the pivotal, randomized, controlled trials of biologic therapies for rheumatoid arthritis (RA) did not show an increase in serious adverse events in biologic-agent-treated patients
compared with placebo-treated patients, there has been concern about the safety of biologic agents in routine practice, because those trials excluded patients with substantial comorbidity.
Indeed, there have been reports of increases in serious adverse events in patients who receive biologic agents; however, before these events can be attributed to the new treatments, the
baseline comorbidity of patients selected for biologic treatment should ascertained. British investigators, therefore, carried out a national, prospective, observational study to identify
the prevalence and types of comorbidity in RA patients treated with biologic agents.
Anyone you share the following link with will be able to read this content: